Weekly Recap: Fiscal 2026 net loss and Phase 2 IHL-42X trial progress

Incannex Healthcare Inc. (NASDAQ:IXHL) reported fiscal 2026 revenue of $0 and a $19.3M net loss (diluted loss $1.66), while advancing its IHL-42X program—completing Phase 2 RePOSA with AHI reductions and launching the Phase 2 DReAMzz dose—confirmation study amid analyst expectations of a Q2 loss ne…